Refine Results
Sort By
From
To
Page 1
Page 1
Cancer drug safety and public health policy : A changing landscape
Description and analysis of recent developments and current trends in health policy with regard to cancer drug safety. Opens with an overview of pharmacovigilance for cancer blockbuster drugs, covering both general considerations and efforts to develop a structured framework for the identification and reporting of adverse drug reactions (ADRs). A number of important examples of serious ADRs to hematology and oncology drugs are then reviewed, with evaluation of the lessons learned and the policy implications of the ensuing legal cases and their settlements. Further, the difficulty of reporting such blockbuster side effects in the medical literature is explored in an empirical study. Significant advances have been achieved in analytic methods for the identification of ADRs, and here there is a particular focus on the value of optimal discriminant analysis. Finally, the impacts on pharmacovigilance and drug safety of the huge fines paid under the U.S. False Claims Act relating to the defrauding of governmental programs also receive careful attention – these fines are playing an important role in changing the landscape for pharmaceutical safety.
Cancer drug resistance : methods and protocols
Discusses the latest techniques used to identify cancer drug resistance determinants at the molecular, cellular, and functional levels. Chapters in this book cover up-to-date topics including tumor-microenvironment cell co-culture methods and microfluidics systems; workflows for functional assessment of drug resistance in vitro and in vivo; quantitative techniques for identifying quiescent blood-flow circulating cells; and single-cell characterization methods, such as mass cytometry.
Anticancer activity in heterocyclic organic structures : A pathway to novel drug development : Part 1
New Directions in Organic & Biological Chemistry, explores the development of cancer therapeutics, focusing on molecular chemistry and advanced drug design approaches. Written by experts in theoretical chemistry and molecular chemistry, they bridge the gap between theoretical chemistry, molecular biology, and drug development. In Part I, they focus on the fundamental properties of heterocyclic compounds and innovative methodologies being employed to enhance therapeutic potential. By exploring various classes of heterocyclic compounds and diverse anticancer mechanisms.
